Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.

In the following months she showed a decreasing trend of BCR-ABL1 levels, with acquisition of DMR and, at the last follow-up, 50 months after imatinib discontinuation, she is in MR 5.0 with undetectable disease.

also in 47,180 other papers